Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cancer Stem Cells: Are We Missing the Target?

Jones, R. J., Matsui, W. H., Smith, B. D. · 2004 · JNCI Journal of the National Cancer Institute

Abstract

Most conventional anticancer agents are nonselective cellular poisons with broad activities against most dividing cells, regardless of whether they are malignant or not; any preferential effects of these agents on cancer cells usually reflect their relatively high rates of cell division. The widely acclaimed success of imatinib mesylate (also known as STI571 or Gleevec, and herein referred to as imatinib) in chronic myeloid leukemia (CML) highlights the enormous possibilities that the development of drugs directed against cancer-specific targets has for improving cancer treatment. Targeted anticancer agents have the potential to favorably influence patient survival by decreasing toxicity and improving disease control. However, recent laboratory and clinical data raise questions about whether new anticancer agents will effectively target relevant subsets of cancer cells. These issues have implications for interpreting results of clinical studies with targeted therapies as well as for the future development of new anticancer treatments. The cytogenetic hallmark of CML, the Philadelphia chromosome, has been an obvious candidate for selective targeting. The Philadelphia chromosome abnormality in CML is characterized by a reciprocal translocation between chromosomes 9 and 22, resulting in the transfer of c-ABL gene sequences from chromosome 9 to a site adjacent to the BCR gene sequences on chromosome 22. This translocation produces a 210-kD Bcr-Abl fusion protein (p210Bcr–Abl) that is a constitutively active tyrosine kinase (1). p210 Bcr–Abl is not only specific for CML, but the genetic translocation also appears to be the initiating oncogenic event: Mouse bone marrow transduced with a retrovirus encoding p210Bcr–Abl produces disease when transplanted into mice (2). Thus, selective targeting of BCR-ABL should be the consummate therapeutic strategy for CML. Imatinib was developed as part of a program to identify drugs that block the unregulated activities of the protein kinases expressed in many cancers. Imatinib is a potent and relatively selective inhibitor of the Abl tyrosine kinases, including Bcr-Abl (3). Moreover, imatinib has demonstrated striking selective activity against CML cell lines and clinical progenitors in vitro, inhibiting more than 90% of CML progenitor cell growth at concentrations (1–10 μM) that have little activity against normal hematopoietic progenitors. The clinical activity of imatinib has mirrored its in vitro activity. Many CML patients who are interferon resistant enter complete cytogenetic remissions with imatinib (4), and even those with accelerating disease can achieve excellent responses after imatinib therapy (5). Results from a large, multicenter, randomized study comparing imatinib to interferon plus cytarabine indicate that the most dramatic responses to imatinib are in newly diagnosed CML patients (6). With a median follow-up of 19 months, 76% of patients who received imatinib had a complete cytogenetic response, compared with 14% of patients who received interferon plus cytarabine. Imatinib was also tolerated better than interferon plus cytarabine; however, there was no survival difference between the two study arms (6). In May 2001, imatinib was initially approved by the Food and Drug Administration as a second-line therapy for CML; the interim results of the multicenter randomized trial (6) led to its recent approval as a first-line therapy for CML. In addition, the new National Comprehensive Cancer Network guidelines for the treatment of CML no longer recommend interferon as the standard of care; only imatinib is recommended as a first-line therapy for patients not undergoing allogeneic transplantation (7). This recommendation was made despite the short follow-up with imatinib relative to the natural history of CML (6) and the established track record of interferon (8). Not only has interferon been proven to prolong the survival of CML patients, but the 10%–20% of patients who achieve a complete cytogenetic remission with interferon have a median survival greater than 10 years, and some of these patients may actually be cured (8). The prevailing wisdom is that the high early-response rates with imatinib will ultimately translate into improved survivals. However, a recent report (9) has suggested that most of the patients who achieved the best responses with imatinib (polymerase chain reaction negativity for the BCR-ABL fusion transcript) may now be showing evidence of disease progression; although the long-term clinical significance of this finding is currently unclear, it raises some concerns about the durability of responses to imatinib. Recent data are beginning to shed light on mechanisms responsible for clinical resistance to imatinib. For example, BCR-ABL gene amplification or mutations may weaken the antitumor effects of imatinib (10). In addition, secondary genetic mutations capable of driving BCR-ABL–independent leukemic growth may also be present, even at initia

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djh095

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 169

Metadata

Authors
Jones, R. J., Matsui, W. H., & Smith, B. D.
Venue
JNCI Journal of the National Cancer Institute
Published
2004-04-20
Volume
96
Issue
8
Pages
583-585
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2113704788
Cited by
169
References
2
FWCI
7.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Stem Cells: Are We Missing the Target? https://app.cochat.ai/papers/10.1093/jnci/djh095
The paper
Jones, R. J., Matsui, W. H., & Smith, B. D. (2004). Cancer Stem Cells: Are We Missing the Target? JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.